Kymera Therapeutics Inc (NASDAQ: KYMR) kicked off on November 20, 2023, at the price of $19.45, up 7.51% from the previous trading day. During the day, the shares moved up to $21.31 and dropped to $19.45 before settling in for the closing price of $19.43. Over the past 52 weeks, KYMR has traded in a range of $9.60-$39.85.
A company in the Healthcare sector has jumped its sales by 284.57% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 10.47%. With a float of $48.14 million, this company’s outstanding shares have now reached $55.04 million.
In an organization with 167 employees, it is important to assess its efficiency. In terms of profitability, gross margin is +93.64, operating margin of -344.37, and the pretax margin is -330.60.
Kymera Therapeutics Inc (KYMR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kymera Therapeutics Inc is 13.25%, while institutional ownership is 92.72%. The most recent insider transaction that took place on Nov 03, was worth 2,781,407. In this transaction Director of this company bought 197,699 shares at a rate of $14.07, taking the stock ownership to the 2,656,191 shares. Before that another transaction happened on Nov 02, when Company’s Director bought 216,406 for $11.64, making the entire transaction worth $2,519,918. This insider now owns 2,552,306 shares in total.
Kymera Therapeutics Inc (KYMR) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/29/2023, the organization reported -$0.9 earnings per share (EPS), lower than consensus estimate (set at -$0.64) by -$0.26. This company achieved a net margin of -330.60 while generating a return on equity of -32.60. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.90% during the next five years compared to -56.21% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Take a look at Kymera Therapeutics Inc’s (KYMR) current performance indicators. Last quarter, stock had a quick ratio of 5.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -3.23 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.01 million. That was better than the volume of 0.54 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 91.09%. Additionally, its Average True Range was 1.37.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 72.42%, which indicates a significant decrease from 96.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 108.68% in the past 14 days, which was higher than the 75.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.91, while its 200-day Moving Average is $23.92. However, in the short run, Kymera Therapeutics Inc’s stock first resistance to watch stands at $21.65. Second resistance stands at $22.41. The third major resistance level sits at $23.51. If the price goes on to break the first support level at $19.79, it is likely to go to the next support level at $18.69. The third support level lies at $17.93 if the price breaches the second support level.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
The company with the Market Capitalisation of 1.16 billion has total of 55,487K Shares Outstanding. Its annual sales at the moment are 46,830 K in contrast with the sum of -154,810 K annual income. Company’s last quarter sales were recorded 4,730 K and last quarter income was -52,870 K.